Cameka Scarborough, MD
Family Medicine · Macon, GANPI 1063588614
Payments from drug & device makers
Across 325 payments — averaging $15.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$801
- Novo Nordisk$632
- Amgen$560
- Lilly USA, LLC$354
- Boehringer Ingelheim$339
- plus $1K from 29 others
What the payments were for
- Food & beverage$5,10498%
- Education$261%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 55 | $1,014 |
| AbbVie(2 entities) | 49 | $801 |
| Novo Nordisk | 68 | $632 |
| Amgen | 27 | $560 |
| Lilly USA, LLC | 26 | $354 |
| Boehringer Ingelheim | 20 | $339 |
| Pfizer | 9 | $180 |
| GSK | 7 | $131 |
| Bayer | 6 | $107 |
| Biohaven Pharmaceuticals, Inc. | 4 | $86 |
| Corium, LLC | 3 | $84 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $80 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $78 |
| Novartis | 4 | $76 |
| Sanofi-aventis U.S. LLC | 4 | $73 |
| Merck | 5 | $72 |
| Abbott | 3 | $70 |
| Dexcom, Inc. | 4 | $62 |
| Mannkind Corporation | 1 | $59 |
| Kowa Pharmaceuticals America, Inc. | 3 | $47 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Eisai Inc. | 2 | $30 |
| Mayne Pharma Commercial LLC | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Merz North America, Inc. | 1 | $19 |
| Exact Sciences | 1 | $19 |
| Bausch Health US, LLC | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
| Astellas Pharma US Inc | 1 | $13 |
| Ironwood Pharmaceuticals, Inc | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIMOVIG$112
How this compares
$5,189 in reported general payments places this provider in the 85th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 118 | $169,791 |
| MounjaroTirzepatide | 59 | $73,262 |
| JardianceEmpagliflozin | 56 | $49,207 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 30 | $41,658 |
| EliquisApixaban | 49 | $39,735 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 61 | $39,651 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $36,477 |
| FarxigaDapagliflozin Propanediol | 41 | $35,991 |
| TrulicityDulaglutide | 30 | $33,169 |
| LinzessLinaclotide | 27 | $28,581 |
| UbrelvyUbrogepant | 16 | $19,010 |
| SynjardyEmpagliflozin/Metformin Hcl | 22 | $16,630 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $14,244 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $12,467 |
| EntrestoSacubitril/Valsartan | 11 | $12,275 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $632 | $169,791118 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Jentadueto | $339 | $111,019150 claims |
| Lilly USA, LLCMounjaro, Trulicity | $354 | $106,43189 claims |
| AbbVieLinzess, Ubrelvy, Synthroid | $801 | $50,39378 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,014 | $50,23560 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $73 | $41,65830 claims |
| PfizerEliquis | $180 | $39,73549 claims |
| GSKTrelegy Ellipta | $131 | $36,47726 claims |
| NovartisEntresto | $76 | $12,27511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Macon
- Frederick BurtonMacon$66K
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.